Payment overview · 2025
General Payments
$209.27
6 reported records · 3 companies
Healthcare provider profile · identity verified
Amy Foster, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · TULSA, OK · NPI 1699847764
Verified facts
What the public records show
CMS Open Payments records show Amy Foster, ARNP received $209.27 in general payments during 2025 across 6 reported records.
Medtronic, Inc. accounted for 78.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$163.49 | 78.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.78 | 12.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.00 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $197.37 | 5 |
| Travel and Lodging | $11.90 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $163.49 | 4 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 713 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 676 | 78 |
| Losartan Potassium | Losartan Potassium | 537 | 63 |
| Jardiance | Empagliflozin | 530 | 68 |
| Ozempic | Semaglutide | 512 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 504 | 65 |
| Omeprazole | Omeprazole | 478 | 62 |
| Gabapentin | Gabapentin | 429 | 49 |
| Metformin Hcl Er | Metformin Hcl | 385 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 354 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 323 | 41 |
| Synthroid | Levothyroxine Sodium | 322 | 40 |
| Montelukast Sodium | Montelukast Sodium | 311 | 38 |
| Eliquis | Apixaban | 303 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 300 | 37 |
| Metformin Hcl | Metformin Hcl | 297 | 34 |
| Furosemide | Furosemide | 285 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 34 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 282 | 50 |
| Simvastatin | Simvastatin | 276 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 266 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 27 |
| Potassium Chloride | Potassium Chloride | 232 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 228 | 43 |
| Mounjaro | Tirzepatide | 227 | 28 |
| Novolog Flexpen | Insulin Aspart | 188 | 32 |
| Carvedilol | Carvedilol | 183 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 164 | 18 |
| Glipizide Er | Glipizide | 161 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 21 |
| Alogliptin | Alogliptin Benzoate | 131 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 130 | 33 |
| Trazodone Hcl | Trazodone Hcl | 120 | 17 |
| Levemir Flexpen | Insulin Detemir | 119 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 36 |
| Calcitriol | Calcitriol | 109 | 20 |
| Fenofibrate | Fenofibrate | 102 | 13 |
| Spironolactone | Spironolactone | 96 | 13 |
| Sertraline Hcl | Sertraline Hcl | 91 | 14 |
| Myrbetriq | Mirabegron | 86 | 12 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 83 | 11 |
| Famotidine | Famotidine | 82 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | 13 |
| Entresto | Sacubitril/Valsartan | 81 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 79 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 75 | 12 |
| Pregabalin | Pregabalin | 74 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 12 |
| Nifedipine Er | Nifedipine | 73 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 12 |
| Buspirone Hcl | Buspirone Hcl | 69 | suppressed |
| Celecoxib | Celecoxib | 68 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 66 | 12 |
| Allopurinol | Allopurinol | 53 | suppressed |
| Baclofen | Baclofen | 53 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Ezetimibe | Ezetimibe | 50 | suppressed |
| Torsemide | Torsemide | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Meloxicam | Meloxicam | 42 | 11 |
| Premarin | Estrogens, Conjugated | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Acarbose | Acarbose | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Glipizide Xl | Glipizide | 34 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 34 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 24 |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 20 |
| Lidocaine | Lidocaine | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 18 |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Prednisone | Prednisone | 23 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Effexor Xr | Venlafaxine Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Procrit | Epoetin Alfa | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Pacerone | Amiodarone Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $209.27 · 6 records | Medtronic, Inc. | CARDIOMEMS, Cologuard Collection Kit, MINIMED 780G | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error